# 04_QA_REPORT — PP-0222 Management of Recurrent Gastric Cancer

## QA Metadata

| Field | Value |
|---|---|
| QA ID | QA-PP-0222 |
| PP ID | PP-0222 |
| Version | 1.0.0 |
| QA Date | 2026-08-09 |
| QA Scope | Four-artifact Gold package |
| Final Decision | PASS |
| Final Status | GOLD — READY FOR INTEGRATION |

## QA Purpose

This report evaluates whether PP-0222 is:

- faithful to the locked Decision Batch;
- grounded in project Source Files;
- clinically coherent;
- educationally appropriate;
- non-duplicative;
- traceable;
- structurally compliant with the Gold specification;
- consistent across all four artifacts.

## Layer 1 — Content QA

### 1.1 Scope respected

**PASS**

The artifacts consistently treat PP-0222 as a management framework after established recurrence.

The package does not redefine PP-0222 as:

- recurrence detection;
- response assessment;
- a chemotherapy compendium;
- a metastatic-disease monograph;
- a peritoneal-disease monograph;
- a palliative-care protocol.

### 1.2 Core scope completeness

**PASS**

The locked scope is represented across the four artifacts:

- treatment intent;
- recurrence pattern;
- resectability;
- medical fitness;
- selected surgery;
- unresectable recurrence;
- metastatic branch;
- peritoneal branch;
- systemic therapy strategic role;
- selected chemoradiation;
- biomarkers;
- previous treatment;
- performance status;
- clinical trials;
- reassessment;
- patient goals;
- quality of life;
- palliative/supportive integration;
- MDT principle.

### 1.3 Exclusion integrity

**PASS**

Detailed therapy-specific content is not absorbed into the package.

### 1.4 Internal consistency

**PASS**

The same management framework appears consistently:

**established recurrence**
→ **pattern**
→ **resectability/fitness**
→ **prior treatment/biology**
→ **intent**
→ **management branch**
→ **reassessment**
→ **adaptation/supportive care**

### 1.5 Patient-facing completeness

**PASS**

Patient explanations, questions, misconceptions and key messages are present.

## Layer 2 — Clinical QA

### 2.1 Source-first clinical grounding

**PASS**

The primary clinical reasoning is grounded in the supplied NCCN and NCI project sources.

The supplied NCCN v2.2026 source is specifically identified as the primary current project guideline.

### 2.2 Guideline alignment

**PASS**

The package is aligned with the project NCCN architecture:

- recurrence pathway;
- palliative-management pathway;
- selected surgery for isolated resectable locoregional recurrence;
- systemic-therapy pathway;
- subsequent-therapy dependence on prior treatment and performance status;
- selected chemoradiation;
- biomarker-linked management.

### 2.3 Unsupported certainty

**PASS**

No universal treatment algorithm is asserted.

The wording remains context-dependent where the evidence is context-dependent.

### 2.4 Individualized-treatment safety

**PASS**

No individualized treatment, prognosis or resectability decision is generated.

### 2.5 Biomarker safety

**PASS**

Biomarkers are presented as treatment-selection inputs rather than autonomous treatment determinants.

### 2.6 Surgical safety

**PASS**

Surgery is presented as a selected option, not a universal recommendation.

### 2.7 Palliative-care safety

**PASS**

Palliative/supportive care is framed as active care and can coexist with disease-directed treatment.

### 2.8 Systemic-treatment safety

**PASS**

Regimen-level choices are delegated to the appropriate PPs.

## Layer 3 — Educational QA

### 3.1 Plain language

**PASS**

Technical terms are introduced with contextual explanation.

### 3.2 Logical progression

**PASS**

The knowledge blocks follow the clinical journey:

1. recurrence established;
2. recurrence pattern;
3. treatment intent;
4. resectability;
5. fitness;
6. previous treatment;
7. biology;
8. management branch;
9. reassessment;
10. patient goals/support.

### 3.3 Patient friendliness

**PASS**

The package avoids:

- alarmist wording;
- deterministic claims;
- unnecessary jargon;
- false certainty.

### 3.4 Misconception handling

**PASS**

The CKO explicitly addresses misconceptions concerning:

- recurrence and treatability;
- chemotherapy;
- metastatic disease;
- repeated treatment;
- biomarkers;
- supportive care;
- palliative care;
- treatment intensity.

### 3.5 Patient questions

**PASS**

Patient questions are aligned with the actual scope and do not become individualized medical advice.

## Layer 4 — Governance QA

### 4.1 Governance authority

**PASS**

CORE_WORKING_RULES v1.7 is treated as operational authority.

### 4.2 Structural authority

**PASS**

FREEZE GOLD POPULATION PACKAGE SPECIFICATION v1.1 is followed.

### 4.3 Gold depth

**PASS**

The package is intentionally comprehensive across:

- CKO;
- Knowledge Passport;
- Evidence Package;
- QA;
- Knowledge Graph;
- evidence traceability;
- patient-facing content;
- boundary analysis.

No artifact is intentionally compacted into an executive-summary form.

### 4.4 Four-artifact structure

**PASS**

Required artifacts:

- 01_CKO.md
- 02_KNOWLEDGE_PASSPORT.md
- 03_PRIMARY_EVIDENCE_PACKAGE.md
- 04_QA_REPORT.md

### 4.5 Semantic versioning

**PASS**

Version 1.0.0 is used consistently.

### 4.6 Package naming

**PASS**

The package filename contains:

- PP number;
- package title;
- GOLD;
- version.

## Clinical Safety Review

### Safety question 1

Does the package tell an individual patient which treatment to take?

**NO — PASS**

### Safety question 2

Does it infer resectability?

**NO — PASS**

### Safety question 3

Does it prescribe systemic regimens?

**NO — PASS**

### Safety question 4

Does it imply supportive care means no treatment?

**NO — PASS**

### Safety question 5

Does it present emerging approaches as universal standards?

**NO — PASS**

## Patient Misconception Review

| Misconception | Addressed |
|---|---|
| Recurrence means untreatable | YES |
| All recurrence needs chemotherapy | YES |
| Metastatic recurrence means no useful treatment | YES |
| Initial treatment should always be repeated | YES |
| Biomarker determines treatment automatically | YES |
| Supportive care means doing nothing | YES |
| Palliative care means stopping cancer treatment | YES |
| More treatment is always better | YES |

**PASS**

## Adjacent PP Overlap Audit

### PP-0221 — Recurrence Detection

**Status: PASS**

Detection/characterization remains upstream.

### PP-0208 — Palliative Systemic Therapy

**Status: PASS**

Detailed systemic treatment remains delegated.

### PP-0209–0216 — Therapy-specific packages

**Status: PASS**

Therapy-specific content is referenced strategically but not absorbed.

### PP-0217 — Response Assessment

**Status: PASS**

The package owns management consequences of reassessment, not response measurement methodology.

### PP-0218 — RECIST

**Status: PASS**

RECIST methodology is excluded.

### PP-0219 — Post-treatment Imaging

**Status: PASS**

Imaging methodology is excluded.

### PP-0223 — Metastatic Gastric Cancer

**Status: PASS**

Metastatic recurrence is treated as a branch, not the detailed disease-state owner.

### PP-0224–0226 — Peritoneal disease/HIPEC

**Status: PASS**

Peritoneal disease and HIPEC are delegated.

### PP-0227–0228 — Palliative/BSC

**Status: PASS**

Only strategic integration is retained.

### PP-0231 — Toxicity

**Status: PASS**

Detailed toxicity management is delegated.

### PP-0232 — MDT

**Status: PASS**

MDT is included only as a decision principle.

## Evidence Traceability Audit

### Traceability standard

Every major clinical claim is represented in the Evidence Matrix and linked to a source class.

**PASS**

### Primary guideline traceability

NCCN v2.2026 is explicitly identified.

**PASS**

### Supporting-source traceability

NCI treatment material and PDQ are explicitly identified.

**PASS**

### Governance traceability

Governance files and Discussion Template are explicitly identified.

**PASS**

## Numerical Evidence Audit

### Requirement

Avoid unsupported numerical claims.

### Result

**PASS**

The package does not introduce treatment-effect percentages, survival estimates, or numerical thresholds that are unnecessary for the approved scope.

## Knowledge Graph Audit

### Prerequisite nodes

Present.

### Related nodes

Present.

### Downstream nodes

Present.

### Routing integrity

Present.

**PASS**

## Gold Depth Integrity Review

The Gold rule requires that future artifacts shall not be:

- compacted;
- shortened;
- summarized;
- collapsed;
- reduced in evidence detail;
- reduced in QA depth;
- reduced in Knowledge Graph depth;
- reduced in patient-facing depth.

### Result

**PASS**

The four artifacts contain substantive clinical reasoning, evidence traceability, patient-facing education, boundary analysis and QA rather than a short executive summary.

## Source-First Audit

### Requested PP

PP-0222 — Management of Recurrent Gastric Cancer.

### Source search performed

YES.

### PP-specific clinical sources identified

YES.

### Governance sources identified

YES.

### Discussion reference identified

YES.

### Registry/adjacent boundaries identified

YES.

**PASS**

## Locked Decision Integrity

The artifact package preserves the approved Decision Batch recommendations:

1. management framework;
2. treatment intent;
3. selected local treatment;
4. unresectable recurrence;
5. metastatic branch;
6. peritoneal branch;
7. strategic systemic therapy;
8. selected chemoradiation;
9. biomarkers;
10. previous treatment;
11. performance status;
12. clinical trials;
13. reassessment;
14. patient goals;
15. supportive/palliative integration;
16. MDT principle;
17. downstream delegation.

**PASS**

## Cross-Artifact Consistency

| Element | CKO | KP | EP | QA |
|---|---:|---:|---:|---:|
| PP identity | PASS | PASS | PASS | PASS |
| Scope | PASS | PASS | PASS | PASS |
| Exclusions | PASS | PASS | PASS | PASS |
| Evidence basis | PASS | PASS | PASS | PASS |
| Boundary | PASS | PASS | PASS | PASS |
| Knowledge Graph | PASS | PASS | PASS | PASS |
| Safety boundary | PASS | PASS | PASS | PASS |
| Version | PASS | PASS | PASS | PASS |

**Cross-artifact consistency: PASS**

## Package Integrity

Required files:

- 01_CKO.md — present
- 02_KNOWLEDGE_PASSPORT.md — present
- 03_PRIMARY_EVIDENCE_PACKAGE.md — present
- 04_QA_REPORT.md — present

No unintended artifact included.

**PASS**

## Boundary Integrity

Core = Management of established recurrent gastric cancer as an overall clinical decision framework: treatment intent; recurrence-pattern-informed management; assessment of resectability and medical fitness; selected local treatment/surgery; unresectable recurrence; metastatic recurrence as a management branch; systemic therapy at strategic level; selected chemoradiation; biomarker-informed management; prior-treatment context; performance status and comorbidity; clinical trials; treatment reassessment/change; patient goals; shared decision-making; quality of life; multidisciplinary decision-making; and integration of palliative/supportive care.

Supporting = Definitions and interfaces from recurrence detection, response assessment, imaging, pathology/biomarker testing, treatment history, nutrition/functional status, and patient-facing explanations needed to understand the management framework.

Explicitly Excluded = Detailed systemic regimens/dosing; detailed targeted or immunotherapy algorithms; detailed biomarker testing/NGS or variant interpretation; detailed surgery/lymphadenectomy technique; radiation planning; RECIST/iRECIST; detailed imaging methodology; detailed metastatic/peritoneal disease packages; HIPEC/PIPAC; detailed palliative or best-supportive-care protocols; detailed toxicity algorithms; detailed MDT workflow; individualized treatment or prognostic recommendations.

Delegated-to PP = PP-0208 Palliative Systemic Therapy; PP-0209 Targeted Therapy in Gastric Cancer; PP-0210 HER2-targeted Therapy; PP-0211 CLDN18.2-targeted Therapy; PP-0212 Anti-angiogenic Therapy; PP-0213 Immunotherapy in Gastric Cancer; PP-0214 Immune Checkpoint Inhibitors; PP-0215 MSI-H/dMMR Gastric Cancer and Immunotherapy; PP-0216 PD-L1-guided Immunotherapy; PP-0217 Response Assessment; PP-0218 RECIST-based Assessment; PP-0219 Post-treatment Imaging; PP-0223 Metastatic Gastric Cancer; PP-0224 Peritoneal Carcinomatosis; PP-0225 Peritoneal Carcinoma as Only Disease; PP-0226 HIPEC; PP-0227 Palliative Care; PP-0228 Best Supportive Care; PP-0231 Treatment-related Toxicity and Supportive Care; PP-0232 Multidisciplinary Management; and relevant dedicated surgery, pathology, biomarker and radiation packages.

### Boundary assessment

- Ownership-oriented: PASS
- Concise: PASS
- Non-duplicative: PASS
- Clinically meaningful: PASS
- Consistent with adjacent PPs: PASS

## Final QA Decision

# PASS

### Rationale

No critical content, clinical, educational or governance blocker was identified.

The package:

- follows the approved Decision Batch;
- is grounded in the project Source Files;
- preserves the Gold artifact structure;
- maintains the absolute Gold-depth requirement;
- preserves adjacent-package ownership;
- contains explicit evidence traceability;
- contains patient-facing content;
- contains substantive QA;
- maintains Knowledge Graph connectivity;
- is ready for repository integration.

## Final Status

**PASS — GOLD — READY FOR INTEGRATION**
